These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 30486477)
1. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells. Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477 [TBL] [Abstract][Full Text] [Related]
2. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo. Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239 [TBL] [Abstract][Full Text] [Related]
3. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA. Qin X; Fang L; Chen F; Gou S Eur J Med Chem; 2017 Sep; 137():167-175. PubMed ID: 28586717 [TBL] [Abstract][Full Text] [Related]
4. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087 [TBL] [Abstract][Full Text] [Related]
5. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity. Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585 [TBL] [Abstract][Full Text] [Related]
6. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon. Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526 [TBL] [Abstract][Full Text] [Related]
7. Alternative mechanism of action of the DNP Pt Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020 [TBL] [Abstract][Full Text] [Related]
8. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood. Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446 [TBL] [Abstract][Full Text] [Related]
9. Potent Chlorambucil-Platinum(IV) Prodrugs. Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383 [TBL] [Abstract][Full Text] [Related]
10. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy. Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698 [TBL] [Abstract][Full Text] [Related]
11. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance. Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328 [TBL] [Abstract][Full Text] [Related]
14. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. Li L; Huang X; Huang R; Gou S; Wang Z; Wang H Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells. Elias MG; Aputen AD; Fatima S; Mann TJ; Karan S; Mikhael M; de Souza P; Gordon CP; Scott KF; Aldrich-Wright JR Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125821 [TBL] [Abstract][Full Text] [Related]
17. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1. Xu Z; Hu W; Wang Z; Gou S Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068 [TBL] [Abstract][Full Text] [Related]
18. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin. Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514 [TBL] [Abstract][Full Text] [Related]
19. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways. Chen F; Qin X; Xu G; Gou S; Jin X Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821 [TBL] [Abstract][Full Text] [Related]
20. The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions. Gabano E; Ravera M; Trivero F; Tinello S; Gallina A; Zanellato I; Gariboldi MB; Monti E; Osella D Dalton Trans; 2018 Jun; 47(25):8268-8282. PubMed ID: 29892758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]